⚡ QUICK FACTS — GLAUCOMA


🔴 Acute angle-closure	MEDICAL EMERGENCY — seek help immediately
👁️ What it is	Group of eye conditions damaging the optic nerve
🌍 Global rank	Second leading cause of blindness worldwide
🏆 Over-60 rank	Leading cause of blindness for people over 60
📊 Americans with glaucoma	Over 3 million
⚠️ Unaware they have it	~50% of patients
📊 Vision loss risk	~5% lose sight; ~10% sight impairment
🧬 ICD-10 code	H40
🎯 Screening (under 40)	Every 5–10 years
🎯 Screening (40–54)	Every 2–4 years
🎯 Screening (55–64)	Every 1–3 years
🎯 Screening (65+)	Annually
💊 New drug — Ripasudil	IOP reduction 2.2–3.5 mmHg
💊 New drug — Netarsudil	IOP reduction 5.5–6.8 mmHg
🔬 MIGS IOP reduction	20–30%
🔬 MIGS medication reduction	20–40%
🏅 Hospital accreditation	Turkish Ministry of Health certified + international standards

⚠️ MEDICAL EMERGENCY NOTICE

If you experience sudden severe eye pain, headache, nausea, blurred vision, or halos around lights — this may be acute angle-closure glaucoma. Seek emergency medical care immediately. Untreated acute angle-closure glaucoma can cause permanent vision loss within hours.

🏅 HOSPITAL ACCREDITATION

Every glaucoma treatment at Revitalize in Turkey is performed in a contracted facility holding:

Turkish Ministry of Health Certification — mandatory national regulatory standard
International accreditation equivalent to JCI standards
Full ophthalmological diagnostic and surgical capability

View contracted facilities and accreditation details →

👨‍⚕️ SURGEON IDENTITY & CREDENTIALS — E-E-A-T

Serkan Bilis, MD

Specialty: Ophthalmology — Glaucoma and Medical Retina
Board Certification: Turkish Board of Ophthalmology
Professional Memberships: Turkish Ophthalmological Association; European Glaucoma Society (EGS)
Special expertise: Glaucoma diagnosis and management, MIGS, trabeculectomy, laser treatments (SLT/LPI), intraocular pressure management

View all surgeon profiles and credentials →

For independent UK patient guidance on glaucoma symptoms, diagnosis, and treatment, the NHS glaucoma overviewprovides authoritative information.

💬 VERIFIED PATIENT REVIEWS

“I was diagnosed with open-angle glaucoma after a routine eye check at Revitalize. The specialist explained every aspect of the condition clearly and put a management plan in place immediately. Two years on, my IOP is well-controlled and my peripheral vision has been preserved. I’m incredibly grateful for the early detection.” — Robert H., London, glaucoma management, 2024 ⭐⭐⭐⭐⭐

“I’d been struggling with elevated eye pressure for years in the UK but wasn’t getting the results I needed from eye drops alone. The team at Revitalize assessed me for MIGS and the procedure has been transformative — my IOP is down significantly and I’ve reduced my medication. Highly recommended.” — Kathleen D., Manchester, MIGS glaucoma surgery, 2023 ⭐⭐⭐⭐⭐

👉 Watch video testimonials →

Introduction

Glaucoma is one of the most serious and consequential conditions in all of ophthalmology — not because it is rare, but because it is both extraordinarily common and extraordinarily silent. It is the second leading cause of blindness worldwide, the leading cause of blindness for people over 60, and affects more than 3 million Americans — with approximately 50% unaware they have the condition.

Glaucoma is called the “silent thief of sight” because in its most common form — open-angle glaucoma — it causes no pain, no redness, and no noticeable symptoms in its early stages. Vision is lost gradually, beginning with peripheral vision, and by the time a patient notices changes to their sight, significant and irreversible optic nerve damage has often already occurred.

The most important fact about glaucoma is this: early detection and consistent treatment can preserve vision in the vast majority of patients. With approximately 5% of patients losing their sight and 10% experiencing significant impairment, those who are screened regularly, diagnosed early, and managed appropriately have an excellent prognosis. At Revitalize in Turkey, our glaucoma specialists provide comprehensive diagnosis, management, and treatment — including the latest minimally invasive surgical options — in internationally accredited facilities.

What Is Glaucoma? Definition and Types

Glaucoma is not a single disease but a group of eye conditions that share a common mechanism: damage to the optic nerve — the structure that transmits visual information from the eye to the brain. This damage most commonly results from elevated intraocular pressure (IOP), though it can also occur at normal pressure levels, making regular screening essential for all at-risk individuals.

The ICD-10 code for glaucoma is H40, reflecting its classification as a distinct and clinically significant group of eye disorders.

The Four Main Types of Glaucoma

Open-Angle Glaucoma (most common) The trabecular meshwork — the eye’s primary drainage system — gradually loses efficiency, causing a slow, progressive rise in intraocular pressure. This type typically has no early symptoms. Peripheral vision loss develops gradually and may not be noticed until significant damage has occurred. It is, overwhelmingly, the most common form of glaucoma.

Acute Angle-Closure Glaucoma (medical emergency) When the drainage angle between the iris and cornea closes suddenly, intraocular pressure rises rapidly and dramatically. This is a medical emergency. Symptoms are severe and sudden: intense eye pain, headache, nausea and vomiting, blurred vision, and halos around lights. Untreated acute angle-closure glaucoma can cause permanent vision loss within hours. If you experience these symptoms, seek emergency medical care immediately.

Normal-Tension Glaucoma The optic nerve is damaged despite intraocular pressure being within the normal range. This form is less well understood but may involve increased sensitivity of the optic nerve to pressure, or compromised blood flow to the optic nerve.

Pigmentary Glaucoma Pigment granules shed from the iris accumulate in and block the trabecular meshwork — the eye’s drainage system — raising intraocular pressure. This type is more common in younger, short-sighted individuals.

Type	Key Feature	Urgency
Open-angle glaucoma	Most common; gradual; often no symptoms	Manage routinely; screen regularly
Acute angle-closure	Sudden severe symptoms	Medical emergency — immediate care
Normal-tension	Optic nerve damage at normal IOP	Regular monitoring required
Pigmentary	Iris pigment blocks drainage	Manage and monitor

7 Essential Facts About Glaucoma

Fact 1: Glaucoma Is Called the “Silent Thief of Sight” for Good Reason

The defining clinical challenge of glaucoma is its asymptomatic early course. In open-angle glaucoma — the most prevalent type — the optic nerve is being progressively damaged, and peripheral vision is being irreversibly lost, with no pain, no redness, no warning signals of any kind to alert the patient.

Over 3 million Americans have glaucoma. Approximately 50% are unaware they have it. These figures represent not a failure of treatment but a failure of detection — patients who are screened regularly and diagnosed early can be managed effectively to preserve their vision for life. Patients who are not screened go undetected until vision loss is already significant and irreversible.

This is why the glaucoma screening schedule exists, why it is stratified by age and risk factors, and why following it precisely is one of the most important acts of preventive eye healthcare any individual can undertake.

Fact 2: Multiple Risk Factors Determine Who Is Most at Risk

Understanding who is at highest risk for glaucoma — and ensuring those individuals are screened at the most frequent intervals — is the most effective population-level strategy for reducing glaucoma blindness.

Key glaucoma risk factors:

Risk Factor	Impact
Age over 55	Primary risk factor — risk increases with age
Family history of glaucoma	Genetic predisposition significantly increases risk
African, Hispanic, East Asian ethnicity	Higher prevalence in these populations
Diabetes	Increases risk of multiple types of glaucoma
High blood pressure	Associated with elevated intraocular pressure
Heart disease	Associated with compromised optic nerve blood flow
Eye injuries	Trauma can damage the drainage system
Long-term steroid use	Can raise intraocular pressure

Patients with multiple risk factors — for example, an African American patient over 55 with a family history of glaucoma — should be at the most aggressive end of the screening schedule for their age group, ideally with annual examinations from age 40 onwards.

Fact 3: Regular Screening to the Correct Schedule Is the Best Protection

Because glaucoma so often has no symptoms until vision loss is advanced, adherence to the recommended screening schedule is the single most important thing any individual can do to protect themselves from glaucoma blindness.

Recommended glaucoma screening frequency:

Age Group	Screening Frequency
Under 40 (no risk factors)	Every 5–10 years
40–54	Every 2–4 years
55–64	Every 1–3 years
65 and over	Annually
High-risk (any age)	More frequently — discuss with your ophthalmologist

Diagnostic tests used in glaucoma screening:

Test	What It Measures	Frequency
Eye pressure measurement (tonometry)	Intraocular pressure	Annually or more frequently for high-risk
Visual field test	Peripheral and central vision; blind spots	Annually or as recommended
Optic nerve examination	Health and appearance of the optic nerve	Annually or as recommended
Gonioscopy	Drainage angle structure	As indicated
Optical coherence tomography (OCT)	Detailed optic nerve imaging	As indicated

Fact 4: Glaucoma Treatment Options Are Comprehensive and Effective

The treatment landscape for glaucoma is extensive — from first-line medicated eye drops through to cutting-edge minimally invasive surgical procedures. Treatment is highly effective when initiated early and managed consistently.

First-line treatment — medicated eye drops:

The first-line treatment for most glaucoma patients is prescription eye drops, which work by either reducing fluid production in the eye or improving drainage. Commonly used medications include apraclonidine, brimonidine, epinephrine, and timolol. Side effects can include blurred vision, fatigue, and dry eyes — and patients should discuss these with their ophthalmologist to optimise the medication regime.

Newer medications:

Medication	IOP Reduction	Notes
Ripasudil (Glanatec®)	2.2–3.5 mmHg	Trough 2.6 mmHg / peak 3.7 mmHg
Netarsudil (Rhopressa®)	5.5–6.8 mmHg	Strong IOP reduction
Omlonti	Variable	FDA approved; improves aqueous drainage

Laser treatments:

Selective Laser Trabeculoplasty (SLT) — used for open-angle glaucoma; targets the trabecular meshwork to improve fluid drainage; well tolerated with minimal side effects
Laser Peripheral Iridotomy (LPI) — used for angle-closure glaucoma; creates a small opening in the iris to allow fluid to bypass the blocked drainage angle

Surgical interventions:

Trabeculectomy — creates a new drainage pathway by removing a piece of the trabecular meshwork; effective for lowering IOP but carries risks including blurred vision, infection, and cataracts
Drainage devices — implantable devices that provide an alternative drainage pathway for aqueous humour
MIGS (Minimally Invasive Glaucoma Surgery) — the most significant surgical advance in glaucoma treatment in recent decades

🎯 MID-PAGE CTA

Concerned About Glaucoma? Book a Comprehensive Eye Assessment.

Our ophthalmology specialists at Revitalize in Turkey offer comprehensive glaucoma screening, diagnosis, and treatment — including the latest MIGS procedures — in internationally accredited facilities.

📱 WhatsApp — Fast response, typically within 2 hours Message on WhatsApp →

📄 Download our Eye Health Guide PDF — Glaucoma overview, screening schedule, treatment comparison, and what to expect at Revitalize in Turkey Download Free PDF →

📅 Book a UK Meeting — London or Manchester Book London → | Book Manchester →

Fact 5: MIGS — The Most Important Advance in Glaucoma Surgery

Minimally Invasive Glaucoma Surgery (MIGS) represents the most significant development in glaucoma surgical treatment in a generation — offering meaningful IOP reduction with substantially less risk, faster recovery, and fewer complications than traditional glaucoma surgery.

MIGS procedures reduce intraocular pressure by 20 to 30% and reduce medication use by 20 to 40%. They are performed through tiny incisions — often at the same time as cataract surgery — and typically allow patients to return to normal activities within days rather than weeks.

The micropulse glaucoma laser is another option for patients who are not suitable for traditional surgery. It works by gently opening the eye’s drainage system to improve fluid flow, without the thermal damage associated with conventional laser approaches.

MIGS is particularly valuable for patients with mild to moderate glaucoma who are not well controlled on eye drops alone, or who want to reduce their medication burden.

Fact 6: Glaucoma and Its Connections to Other Eye Conditions

Glaucoma frequently coexists with and is influenced by other eye conditions — a complexity that requires comprehensive ophthalmic assessment rather than isolated treatment of elevated IOP alone.

Glaucoma and cataracts — a common pairing in older adults. These conditions can worsen each other’s effects, and combined cataract surgery with MIGS implantation can address both conditions simultaneously — an increasingly common and effective approach.

Glaucoma and diabetes — diabetic patients face elevated glaucoma risk. Long-standing diabetic retinopathy can cause a specific form of glaucoma called neovascular glaucoma, where abnormal new blood vessels develop and block the drainage angle, causing severe and rapid IOP elevation.

Glaucoma and macular degeneration — while distinct conditions, both cause progressive vision loss in older adults and can coexist. Patients with macular degeneration should be regularly assessed for glaucoma given the overlapping risk profile.

Glaucoma and age — while glaucoma can occur at any age (including in newborns, children, and young adults aged 20 to 50), the risk increases substantially from age 55 onwards.

Fact 7: Recent Research Is Transforming Glaucoma Treatment

The glaucoma research landscape is moving at pace — with gene therapy, novel pharmaceuticals, AI-assisted diagnosis, and advanced surgical technology all promising to transform how this condition is managed in the coming years.

Recent and emerging advances in glaucoma:

Innovation	Description	Status
Gene therapy (MMP-3)	Targets genes controlling trabecular meshwork function	Research — UPMC Vision Institute leading human trials
Ripasudil (Glanatec®)	ROCK inhibitor eye drop — IOP reduction 2.2–3.5 mmHg	Available
Netarsudil (Rhopressa®)	ROCK inhibitor — IOP reduction 5.5–6.8 mmHg	Available
Omlonti	Novel aqueous outflow drug	FDA approved
Eyemate microelectronic sensor	Implantable IOP monitoring sensor	In development
AI-assisted diagnosis	Early detection and disease progression tracking	Advancing rapidly
Stem cell treatments	Optic nerve regeneration and neuroprotection	Research phase

The UPMC Vision Institute is at the forefront of clinical research in this space, with human trials for gene therapy and stem cell-based treatments anticipated as these approaches advance through preclinical development.

Glaucoma Symptoms: What to Watch For

Understanding the symptoms of glaucoma — and knowing which symptoms represent a medical emergency — is essential for every patient and every at-risk individual.

Open-angle glaucoma (the common form):

Progressive peripheral vision loss — often described as tunnel vision
Not noticed until damage is already significant
No pain, no redness, no warning

Acute angle-closure glaucoma (medical emergency):

Sudden intense eye pain
Severe headache
Nausea and vomiting
Blurred vision
Halos around lights
Seek emergency care immediately — this is a sight-threatening emergency

Normal-tension and chronic glaucoma:

Gradual peripheral vision loss
Difficulty adapting to changes in light levels
In children: excessive blinking, tearing, worsening nearsightedness

Living With Glaucoma

For patients managing glaucoma, the combination of consistent medical treatment, lifestyle support, and regular monitoring provides the best long-term prognosis for vision preservation.

Practical daily strategies:

Adjust home lighting to reduce glare and improve visibility in dim areas
Use visual aids — magnifying glasses, large-print materials, high-contrast tools
Rearrange the home environment to make navigation safer as peripheral vision changes
Engage with support groups — connecting with other glaucoma patients provides emotional support and practical strategies

Lifestyle factors that support glaucoma management:

Aerobic exercise — regular moderate exercise can help lower intraocular pressure
Mediterranean diet — omega-3 fatty acids and antioxidant-rich foods support eye health
Eye protection — protective eyewear prevents injuries that can worsen drainage problems
Avoiding prolonged steroid use — if unavoidable, closer IOP monitoring required

Approximate vision loss risk with treatment:

~5% of treated patients lose their sight
~10% experience significant sight impairment
The vast majority of patients with early diagnosis and consistent treatment preserve their vision for life

Eye Care at Revitalize in Turkey

At Revitalize in Turkey, glaucoma patients receive comprehensive ophthalmological care — from detailed screening and diagnostic assessment through to advanced treatment including the full range of laser procedures, MIGS, and trabeculectomy — in internationally accredited hospital facilities with dedicated UK patient support.

Why UK patients choose Revitalize in Turkey for glaucoma care:

Specialist glaucoma ophthalmologists with expertise in both medical and surgical management
Full diagnostic capability — tonometry, visual field testing, OCT, gonioscopy
Full treatment range — eye drops, SLT, LPI, MIGS, trabeculectomy, drainage devices
Access to newer medications including Ripasudil and Netarsudil
Accredited hospital facilities — Turkish Ministry of Health certification and international standards
UK consultation meetings in London and Manchester
Dedicated UK patient coordinators throughout your journey
21+ years serving UK patients — trusted, proven medical tourism pathway

View our eye treatment services → View contracted facilities and accreditation →

📅 UPCOMING UK CONSULTATION MEETINGS

Londen

📍 Central London (address confirmed on booking) Upcoming dates: [Insert confirmed dates] Book London →

Manchester

📍 Central Manchester (address confirmed on booking) Upcoming dates: [Insert confirmed dates] Book Manchester →

Common Myths About Glaucoma — Debunked

Myth: Glaucoma only affects elderly people. Reality: Glaucoma can occur at any age — including in newborns, young children, and adults aged 20 to 50. Age is the primary risk factor, but glaucoma is not exclusively a condition of old age.

Myth: Glaucoma always involves high eye pressure. Reality: Normal-tension glaucoma causes optic nerve damage at completely normal intraocular pressure levels. IOP is a key risk factor and management target, but it is not always elevated in glaucoma.

Myth: Glaucoma always causes noticeable symptoms. Reality: Open-angle glaucoma — the most common type — typically causes no symptoms until significant vision loss has occurred. Regular screening is the only way to detect it early.

Myth: Glaucoma means inevitable blindness. Reality: With early detection and consistent treatment, most glaucoma patients preserve their vision for life. Only approximately 5% lose their sight and 10% suffer significant impairment.

📋 FAQ — STRUCTURED Q&A (MAPS TO SCHEMA ABOVE)

Q: What is glaucoma? A: A group of eye conditions damaging the optic nerve — typically from elevated intraocular pressure — that is the second leading cause of blindness worldwide and the leading cause in people over 60. Over 3 million Americans have it; ~50% are unaware. ICD-10 code: H40.

Q: What are the types of glaucoma? A: Open-angle (most common; gradual; often no symptoms); Acute angle-closure (medical emergency — sudden severe pain, headache, nausea, blurred vision, halos); Normal-tension (optic nerve damage at normal IOP); Pigmentary (iris pigment blocks drainage).

Q: What are the symptoms of glaucoma? A: Open-angle: gradual peripheral vision loss — no pain or warning. Acute angle-closure: sudden intense eye pain, headache, nausea, blurred vision, halos — medical emergency, seek care immediately. Chronic: gradual peripheral loss, difficulty adapting to light.

Q: How is glaucoma treated? A: Eye drops (apraclonidine, brimonidine, timolol — first line); newer drugs Ripasudil (2.2–3.5 mmHg IOP reduction) and Netarsudil (5.5–6.8 mmHg); FDA-approved Omlonti; SLT laser (open-angle); LPI laser (angle-closure); trabeculectomy; MIGS (IOP 20–30% reduction; medication 20–40% reduction); drainage devices.

Q: How often should I be screened for glaucoma? A: Under 40: every 5–10 years. Ages 40–54: every 2–4 years. Ages 55–64: every 1–3 years. Ages 65+: annually. High-risk patients: discuss more frequent screening with your ophthalmologist.

Q: What are the chances of vision loss from glaucoma? A: ~5% of patients lose their sight; ~10% experience significant impairment. The vast majority of patients with early detection and consistent treatment preserve their vision for life.

📲 THREE WAYS TO START

1. WhatsApp — Fastest Response

Message on WhatsApp → Ask about glaucoma screening, treatment options, MIGS, costs, or anything else. Response typically within 2 hours.

2. Download the Free Eye Health Guide PDF

Download Free PDF → Glaucoma overview, type comparison, screening schedule, treatment options (including MIGS), and what to expect at Revitalize in Turkey.

3. Book a UK Meeting

Book London → | Book Manchester →